Causes of Elevated AST and ALT
The most common causes of elevated AST and ALT are nonalcoholic fatty liver disease (NAFLD) and alcohol-induced liver disease, with NAFLD affecting 20-30% of the general population and up to 90% of diabetics. 1
Understanding the Pattern of Elevation
The pattern and magnitude of aminotransferase elevation provides critical diagnostic clues:
Hepatocellular vs. Non-Hepatic Causes
ALT is highly specific for liver injury due to low concentrations in skeletal muscle and kidney, whereas AST elevation can originate from heart, skeletal muscle, kidneys, brain, and red blood cells 1. When AST rises disproportionately higher than ALT, you must actively consider non-hepatic sources including hemolysis, myopathy, thyroid disease, and exercise 1.
Severity Classification
Aminotransferase elevations are classified as:
- Mild: <5× upper reference limit
- Moderate: 5-10× upper reference limit
- Severe: >10× upper reference limit 1
Common Causes (Mild Elevations)
For mild aminotransferase increases, the differential includes:
Most Common:
- NAFLD (prevalence 20-30% general population, 70% with obesity, 90% with diabetes)
- Alcohol-induced liver disease (AST:ALT ratio typically >2, versus <1 in NAFLD) 1
Uncommon:
- Drug-induced liver injury (DILI)
- Hepatitis B and C
- Hereditary hemochromatosis 1
Rare:
- Alpha-1-antitrypsin deficiency
- Autoimmune hepatitis
- Wilson disease 1
Additional Hepatic Causes
Beyond fatty liver disease, hepatocellular injury causing ALT/AST elevation includes:
- Acute or chronic viral hepatitis (HAV, HBV, HCV, HEV)
- Acute Budd-Chiari syndrome
- Ischemic hepatitis
- Medications/toxins
- Hemochromatosis 1, 2
Critical Non-Hepatic Causes
When evaluating markedly elevated AST (>400 U/L), skeletal muscle damage accounts for 54.2% of cases, cardiac muscle damage 39.1%, and hematologic disorders 6.7% 3. This is particularly important because:
- Muscle injury from intensive exercise (especially weight lifting), rhabdomyolysis, or statin therapy can mimic acute liver injury 4
- Cardiac causes include myocardial infarction and heart failure
- Check creatine kinase (CK) levels to confirm muscle origin 4
Special Populations and Contexts
Cancer Patients on Immunotherapy
In patients receiving immune checkpoint inhibitors, consider immune-mediated liver injury (ILICI) when ALT rises ≥3× ULN from normal baseline or ≥2× from elevated baseline. However, also evaluate for hepatic metastases, biliary obstruction, hepatic vein thrombosis, and systemic infections 2.
NASH Clinical Trial Patients
ALT elevation ≥5× ULN is rare in NASH alone and should not be attributed to underlying disease without excluding viral hepatitis, autoimmune hepatitis, gallstone disease, or DILI 4.
Malignancy-Related Causes
Patients with cancer may have elevated aminotransferases from:
- Hepatic metastases (ALP >1× ULN in 67% with liver mets)
- Biliary obstruction
- Hepatic vein thrombosis
- Congestive heart failure
- Bone metastases (elevating AST/ALP) 2
Rare but Important: Macro-AST
Macro-AST is an immunoglobulin-AST complex causing persistently elevated AST with normal or low ALT, without true liver disease 5, 6. Confirm with polyethylene glycol (PEG) precipitation test showing >70% decline in AST activity, or refrigerated storage showing ~70% decline over 7 days 5.
Prognostic Considerations
The etiology and peak aminotransferase level significantly correlate with mortality. For markedly elevated AST >400 U/L, 30-day mortality rates are: 12.8% for peak <1000 U/L, 26.7% for <3000 U/L, and 50% for ≥3000 U/L 3. Ischemic hepatitis carries 44.2% mortality, malignancy 39.9%, while pancreatobiliary causes have only 1.7% mortality 7.
Key Pitfalls to Avoid
- Don't assume all AST elevation is hepatic—check CK for muscle injury, especially if AST >> ALT 4, 2
- Don't attribute ALT ≥5× ULN to NASH alone during clinical evaluation 4
- Don't overlook gallstone disease in metabolic syndrome patients or those on rapid weight loss diets 4
- Consider macro-AST in isolated, persistent AST elevation with extensive negative workup 5, 6